Your browser is no longer supported. Please, upgrade your browser.
Settings
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own0.30% Shs Outstand123.32M Perf Week-6.30%
Market Cap403.26M Forward P/E- EPS next Y-1.15 Insider Trans0.82% Shs Float121.45M Perf Month-2.68%
Income-128.90M PEG- EPS next Q-0.33 Inst Own68.60% Short Float16.19% Perf Quarter-26.19%
Sales6.70M P/S60.19 EPS this Y0.80% Inst Trans17.63% Short Ratio10.66 Perf Half Y-16.15%
Book/sh2.16 P/B1.51 EPS next Y12.20% ROA-44.30% Target Price8.00 Perf Year-51.12%
Cash/sh1.65 P/C1.98 EPS next 5Y- ROE-51.50% 52W Range2.85 - 8.75 Perf YTD-7.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.63% Beta2.84
Dividend %- Quick Ratio11.30 Sales past 5Y-34.90% Gross Margin- 52W Low14.74% ATR0.15
Employees196 Current Ratio11.30 Sales Q/Q120.00% Oper. Margin- RSI (14)40.55 Volatility4.28% 4.75%
OptionableYes Debt/Eq0.00 EPS Q/Q9.40% Profit Margin- Rel Volume0.89 Prev Close3.38
ShortableYes LT Debt/Eq0.00 EarningsMar 02 AMC Payout- Avg Volume1.84M Price3.27
Recom2.30 SMA20-3.58% SMA50-8.32% SMA200-17.01% Volume1,645,075 Change-3.25%
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Nov-02-11Reiterated Brean Murray Buy $16 → $14
Feb-13-17 02:45PM  Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call GlobeNewswire
Feb-09-17 09:48AM  Why Celldex Therapeutics Stock Fell by Almost 10% in January at Motley Fool
Feb-07-17 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statem
Feb-06-17 07:45AM  3 Stocks That Could Make You Rich at Motley Fool
Feb-03-17 09:30AM  Mergers & Acquisitions Could be a Key Catalyst for Biotech Stocks in 2017: Today's Reports on Cellect Biotechnology and Celldex Therapeutics Accesswire
Feb-01-17 08:14AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys at Motley Fool
Jan-30-17 03:12PM  3 Biotech Stocks I'd Buy Right Now at Motley Fool
Jan-26-17 04:28PM  5 Small-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-20-17 10:41AM  3 Beaten-Down Biotech Stocks You Can Buy Right Now at Motley Fool
Jan-10-17 10:36AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : January 10, 2017
09:09AM  Why Celldex Therapeutics Imploded in 2016 at Motley Fool
Jan-09-17 07:19AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : January 9, 2017
Jan-06-17 01:26PM  Celldex Therapeutics, Inc.'s 3 Best Moves in 2016 at Motley Fool
Dec-24-16 02:52PM  Better Buy: Celldex Therapeutics, Inc. vs. Exelixis at Motley Fool
Dec-22-16 09:36AM  2016's Worst Clinical Failures at Motley Fool
09:24AM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point
Dec-20-16 09:15AM  Latest Reports on Biotech Movers MannKind and Celldex Therapeutics Accesswire
Dec-19-16 02:51PM  How to Value Clinical-Stage Biotech Stocks at Motley Fool
07:18AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : December 19, 2016
Dec-15-16 02:51PM  Celldex Therapeutics, Inc.'s Biggest Failure in 2016 at Motley Fool
Dec-14-16 04:09PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
04:01PM  Celldex Therapeutics Announces Appointment to Board of Directors GlobeNewswire
Dec-13-16 12:22PM  3 Cheap Healthcare Stocks You Can Buy Right Now at Motley Fool
Dec-11-16 12:06PM  Celldex Therapeutics, Inc.'s Biggest Win in 2016 at Motley Fool
Dec-10-16 07:32PM  Is Celldex Therapeutics, Inc. (CLDX) a Good Stock To Buy? at Insider Monkey
Dec-08-16 12:23PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2016
Dec-07-16 11:12AM  Is Celldex Therapeutics (CLDX) Stock a Solid Choice Right Now?
10:01AM  Why Celldex Rallied 22% In November at Motley Fool
Dec-06-16 05:53PM  Why You Should (and Shouldn't) Buy Celldex Therapeutics, Inc. at Motley Fool
Dec-05-16 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F +6.76%
04:01PM  Theresa LaVallee, Ph.D., Joins Celldex Therapeutics Senior Management Team GlobeNewswire
08:01AM  Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Dec-02-16 01:17PM  The Worst Biotech Stocks of 2016 at Motley Fool
Dec-01-16 07:32AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : December 1, 2016 -6.30%
Nov-29-16 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale
04:01PM  Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals GlobeNewswire
08:17AM  Down 11.7%: Is Celldex Therapeutics Now a Buy? at Motley Fool
Nov-23-16 12:47PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 23, 2016
Nov-22-16 10:27AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-21-16 07:03AM  Ready to Get In on Biotech? Check Out These 3 Stocks at Motley Fool +5.64%
Nov-17-16 01:04PM  CELLDEX THERAPEUTICS, INC. Financials
Nov-15-16 02:24PM  Celldex Cancer Drug Did Well in Early Trial (CLDX) at Investopedia
08:03AM  Celldex Stock Up on Positive Data on New Cancer Candidate
Nov-14-16 03:58PM  Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today at Motley Fool +13.89%
08:01AM  Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody GlobeNewswire
Nov-09-16 04:41PM  Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October at Motley Fool +6.61%
03:45PM  Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat
07:26AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2016
Nov-08-16 12:51PM  Why Celldex Therapeutics, Inc. Jumped Higher Today at Motley Fool +14.89%
10:50AM  Celldex 3Q Loss $30M, or 29 Cents a Share (CLDX) at Investopedia
Nov-07-16 06:21PM  Celldex Therapeutics, Inc. Watches Its Cash in Q3, Ready to Expand at Motley Fool +6.47%
05:31PM  Celldex reports 3Q loss
04:07PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Celldex Reports Third Quarter 2016 Results GlobeNewswire
09:37AM  Coverage initiated on Celldex Therapeutics by Aegis Capital
Nov-03-16 08:49AM  Biotech Stock Roundup: Amgen Down on Enbrel Sales, Regeneron's Sarilumab Faces Delay -8.89%
08:15AM  Blog Coverage Celldex Acquires Cancer Medicine Company for $62.5 Million Accesswire
Nov-02-16 01:55PM  Celldex Buys Cancer Drug Co. for $62M Stock (CLDX) at Investopedia
11:33AM  3 Biotech Stocks That Could Double in 12 Months at Motley Fool
09:50AM  9 Biotech Stocks to Put on Your Radar at Kiplinger
Nov-01-16 04:08PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
04:02PM  Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals GlobeNewswire
Oct-31-16 08:50AM  Celldex (CLDX): Will the Stock Surprise in Q3 Earnings?
Oct-26-16 11:15AM  Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc. at Motley Fool
Oct-19-16 11:26AM  ETFs with exposure to Celldex Therapeutics, Inc. : October 19, 2016
07:05AM  Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc. at Motley Fool
Oct-18-16 09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
Oct-17-16 08:02AM  Is This Risky Biotech Stock About to Jump Higher? at Motley Fool
Oct-12-16 08:43AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 12, 2016
Oct-11-16 04:30PM  These 3 Little Biotechs Just Scored Big at Motley Fool -8.96%
09:15AM  Blog Coverage Celldex Phase II Study of Glembatumumabvedotin Show Positive Results Accesswire
09:05AM  Blog Coverage Celldex Phase II Study of Glembatumumabvedotin Show Positive Results
Oct-09-16 07:00AM  Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response GlobeNewswire
Oct-05-16 02:42PM  Three Cancer Plays For The Fourth Quarter Of 2016 at Insider Monkey
02:35PM  4 breakout stocks to watch at MarketWatch
Oct-04-16 05:46PM  Why Endurance Specialty Holdings, Celldex Therapeutics, and Sears Holdings Jumped Today at Motley Fool +6.75%
01:29PM  Why Celldex Therapeutics, Inc. Jumped Higher Today at Motley Fool
09:15AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
08:56AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Doubled Last Year at Motley Fool
08:27AM  3 Beaten-Up Healthcare Stocks: Are They Bargains? at Motley Fool
Sep-30-16 09:44AM  ETFs with exposure to Celldex Therapeutics, Inc. : September 30, 2016 +6.32%
Sep-29-16 10:07AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : September 29, 2016
Sep-28-16 08:07AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 28, 2016 -5.67%
Sep-27-16 04:26PM  Why Celldex Therapeutics, Inc. Ran Higher Today at Motley Fool +11.32%
09:54AM  3 Stocks That Could Make You Rich at Motley Fool
Sep-23-16 11:30AM  Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable GlobeNewswire
Sep-20-16 08:36PM  Celldex Therapeutics Remains a Guessing Game at Investopedia
Sep-14-16 08:20AM  Key FDA Decisions and Trial Results Coming in the Next 2 Months at 24/7 Wall St.
Sep-12-16 10:41AM  ETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2016 +7.54%
08:09AM  Why Celldex Therapeutics, Inc. Stock Sank 28.1% in August at Motley Fool
Sep-08-16 08:05AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
Aug-29-16 11:13AM  ETFs with exposure to Celldex Therapeutics, Inc. : August 29, 2016
Aug-26-16 04:41PM  3 Reasons Celldex Therapeutics, Inc. Stock Could Fall at Motley Fool
Aug-18-16 06:15PM  ETFs with exposure to Celldex Therapeutics, Inc. : August 18, 2016
Aug-17-16 09:29AM  Biotech Industry on the Upswing after Rocky Start to 2016
Aug-16-16 09:55AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016
Aug-12-16 01:42PM  How Risky Is Celldex Therapeutics, Inc.? at Motley Fool
Aug-11-16 08:04AM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
08:01AM  Celldex Appoints Elizabeth Crowley as Chief Product Development Officer GlobeNewswire
Aug-09-16 01:45PM  Celldex Therapeutics (CLDX) Stock Up on Q2 Results
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. The company's lead drug candidates comprise Rintega (CDX-110), a therapeutic vaccine in Phase III clinical studies for the treatment of glioblastoma patients that express an epidermal growth factor receptor variant III, as well as in Phase II study for the treatment of recurrent glioblastoma; Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate (ADC) in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma; and Varlilumab (CDX-1127), an immune modulating antibody is in Phase I study for the treatment of multiple solid tumors. It also has various earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, a fully-human monoclonal ADC that targets T cell immunoglobulin and mucin domain 1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. In addition, the company is developing CDX-0158, which is in a Phase I dose escalation study in refractory gastrointestinal stromal tumors; CDX-3379 that completed a Phase Ib study for adult patients with advanced solid tumors; and a multi-faceted TAM program to generate antibodies that modulate the TAM family of RTKs comprising of Tyro3, AXL, and MerTK. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding. The company is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CATLIN AVERY WSr. VP & CFOSep 02Option Exercise2.8010,00028,00083,586Sep 07 12:59 PM
KELER TIBORExecutive VP & CSOSep 02Buy3.323,0009,96018,868Sep 06 01:04 PM
CATLIN AVERY WSr. VP & CFOJun 03Option Exercise3.0122,84768,81273,586Jun 06 08:26 AM
CATLIN AVERY WSr. VP & CFOMar 09Option Exercise2.8015,00042,00050,739Mar 10 07:59 AM
MAMS MAM Software Group, Inc. daily Stock Chart
MAMS [NASD]
MAM Software Group, Inc.
Index- P/E22.03 EPS (ttm)0.30 Insider Own14.60% Shs Outstand12.50M Perf Week-4.97%
Market Cap81.25M Forward P/E27.08 EPS next Y0.24 Insider Trans0.00% Shs Float9.62M Perf Month-0.46%
Income3.40M PEG- EPS next Q0.03 Inst Own45.90% Short Float0.32% Perf Quarter4.00%
Sales31.80M P/S2.56 EPS this Y27.70% Inst Trans-3.24% Short Ratio5.19 Perf Half Y10.21%
Book/sh0.51 P/B12.75 EPS next Y14.30% ROA15.60% Target Price5.75 Perf Year-4.69%
Cash/sh0.05 P/C135.42 EPS next 5Y- ROE64.80% 52W Range5.10 - 7.77 Perf YTD0.62%
Dividend- P/FCF54.17 EPS past 5Y9.20% ROI26.00% 52W High-16.34% Beta0.06
Dividend %- Quick Ratio0.80 Sales past 5Y4.70% Gross Margin55.30% 52W Low27.45% ATR0.18
Employees230 Current Ratio0.80 Sales Q/Q-6.30% Oper. Margin12.00% RSI (14)47.07 Volatility2.38% 2.08%
OptionableNo Debt/Eq1.47 EPS Q/Q-64.40% Profit Margin10.90% Rel Volume1.73 Prev Close6.54
ShortableYes LT Debt/Eq1.15 EarningsFeb 14 AMC Payout0.00% Avg Volume5.89K Price6.50
Recom3.00 SMA20-1.70% SMA50-0.04% SMA2005.40% Volume10,164 Change-0.61%
Feb-18-17 01:04PM  MAM SOFTWARE GROUP, INC. Financials
Feb-15-17 01:23PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Feb-14-17 05:59PM  MAM SOFTWARE GROUP, INC. Files SEC form 10-Q, Quarterly Report
05:49PM  MAM Software posts 2Q profit
05:02PM  MAM Software Reports Fiscal Second Quarter Results PR Newswire
07:07AM  Q2 2017 MAM Software Group Inc Earnings Release - After Market Close
Feb-01-17 09:00AM  MAM Schedules Second Quarter Results Conference Call for Wednesday, February 15, 2017 PR Newswire
Dec-23-16 04:13PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-12-16 09:30AM  Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart
Dec-09-16 09:44AM  5 Efficient Stocks to Buy for Superlative Returns
09:20AM  Acxiom's LiveRamp Completes Buyouts of Arbor & Circulate
Dec-08-16 08:00AM  Computer Task Group (CTG) Catches Eye: Stock Jumps 6.2%
Dec-07-16 09:27AM  New Strong Buy Stocks for December 7th
Nov-29-16 10:09AM  MAM Software Group, Inc. :MAMS-US: Earnings Analysis: Q1, 2017 By the Numbers : November 29, 2016
Nov-15-16 06:25AM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Nov-14-16 05:49PM  MAM Software posts 1Q profit
05:19PM  MAM SOFTWARE GROUP, INC. Files SEC form 10-Q, Quarterly Report
04:23PM  MAM Software Reports Fiscal First Quarter Results PR Newswire
07:07AM  Q1 2017 MAM Software Group Inc Earnings Release - After Market Close
Nov-07-16 04:01PM  MAM Schedules First Quarter Results Conference Call for Tuesday, November 15, 2016 PR Newswire
Oct-04-16 09:05AM  MAM Software Group, Inc. :MAMS-US: Earnings Analysis: 2016 By the Numbers : October 4, 2016
Sep-30-16 01:04PM  MAM SOFTWARE GROUP, INC. Financials
Sep-26-16 04:55PM  MAM Software posts 4Q profit
04:44PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:37PM  MAM Software Reports Fiscal Fourth Quarter and Full Year Results PR Newswire
07:07AM  Q4 2016 MAM Software Group Inc Earnings Release - After Market Close
Sep-22-16 09:00AM  MAM Software Group Schedules Fourth Quarter and Fiscal Year 2016 Earnings Call for Wednesday, September 28, 2016 PR Newswire
Sep-19-16 04:10PM  MAM Software Group, Inc.: Gathering momentum, can it sustain its performance? -6.40%
Aug-16-16 08:40AM  MAM Software Group (MAMS) Catches Eye: Stock Jumps 5.7%
Jul-01-16 04:32PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Other Events
May-26-16 11:33AM  MAM Software Group, Inc. :MAMS-US: Earnings Analysis: Q3, 2016 By the Numbers : May 26, 2016
May-25-16 09:05AM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
May-16-16 06:12PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition
05:11PM  MAM Software posts 3Q profit
05:03PM  MAM Software Reports Fiscal Third Quarter Results PR Newswire
07:07AM  Q3 2016 MAM Software Group Inc Earnings Release - After Market Close
May-05-16 09:00AM  MAM Software Group Schedules Conference Call for Tuesday May 17, 2016 PR Newswire
May-04-16 11:00AM  MAM Software to Present at the 17th Annual B. Riley & Co. Investors Conference PR Newswire
Apr-06-16 10:00AM  Morelli Group selects MAM to help achieve competitive advantage PR Newswire
Mar-14-16 05:15PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +6.97%
Feb-29-16 09:00AM  MAM to Present at the 28th Annual ROTH Conference PR Newswire -5.44%
Feb-22-16 12:08PM  MAM Software Group, Inc. Earnings Analysis: Q2, 2016 By the Numbers
Feb-17-16 08:35AM  Strength Seen in Baozun (BZUN): Stock Jumps 5.3% in Session
06:04AM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Feb-16-16 09:43PM  Edited Transcript of MAMS earnings conference call or presentation 16-Feb-16 2:00pm GMT
07:35AM  MAM SOFTWARE GROUP, INC. Files SEC form 10-Q, Quarterly Report
Feb-15-16 04:01PM  MAM Software Reports Fiscal Second Quarter Results PR Newswire
07:07AM  Q2 2016 MAM Software Group Inc Earnings Release - Time Not Supplied
Feb-02-16 09:00AM  MAM Announces Fiscal Second Quarter Results Conference Call PR Newswire
Dec-22-15 10:13AM  MAM Software Group, Inc. Earnings Analysis: Q1, 2016 By the Numbers
Dec-16-15 04:39PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Dec-08-15 09:00AM  MAM Software Announces Final Results of Its Tender Offer PR Newswire
Dec-07-15 11:28AM  Is Tenax Therapeutics Inc (TENX) Going to Burn These Hedge Funds? at Insider Monkey -5.16%
06:02AM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi
Dec-03-15 04:06PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure
Dec-02-15 09:00AM  MAM Software Announces Preliminary Results of Its Tender Offer and Closing of Financing PR Newswire
Nov-27-15 09:26AM  Is The McClatchy Company (MNI) A Good Stock To Buy? at Insider Monkey
Nov-24-15 05:37PM  Should You Buy Shares of Covisint Corp (COVS)? at Insider Monkey
Nov-19-15 09:00AM  MAM Software to Present at LD Micro Conference on December 3 PR Newswire
Nov-13-15 05:22PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
08:05AM  GTT Communications (GTT) in Focus: Stock Jumps 7.4%
Nov-12-15 05:07PM  MAM Software posts 1Q profit
04:21PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  MAM Software Reports Fiscal First Quarter Results PR Newswire
07:07AM  Q1 2015 MAM Software Group Inc Earnings Release - Time Not Supplied
Nov-05-15 09:34AM  Will MAM Software (MAMS) Continue to Surge Higher?
Oct-31-15 11:52AM  MAM Software Group, Inc. Announces Tender Offer to Purchase up to 2,000,000 Shares of its Common Stock PR Newswire
Oct-30-15 09:00AM  MAM Announces Fiscal First Quarter Results Conference Call PR Newswire
Oct-19-15 05:09PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial State
04:05PM  MAM Software Welcomes Brian H. Callahan as New Chief Financial Officer PR Newswire
Sep-25-15 04:02PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
02:14PM  Edited Transcript of MAMS earnings conference call or presentation 25-Sep-15 1:00pm GMT
Sep-24-15 04:10PM  MAM Software Reports Fiscal Fourth Quarter and Full Year Results PR Newswire
04:06PM  MAM SOFTWARE GROUP, INC. Files SEC form 10-K, Annual Report
07:07AM  Q4 2015 MAM Software Group Inc Earnings Release - Time Not Supplied
Sep-15-15 09:23AM  MAM Announces Fiscal Fourth Quarter and Full Year Results Conference Call PR Newswire
Jul-23-15 09:00AM  MAM wins prestigious Alliance 'Outstanding Technology Partner' Award PR Newswire
Jul-01-15 12:00PM  MAM Software acquires Origin Software Solutions PR Newswire
May-12-15 05:22PM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibit
May-06-15 07:33PM  MAM Software posts 3Q profit +5.07%
05:00PM  MAM Software Reports Fiscal Third Quarter Financial Results 6 May 2015 at noodls
04:19PM  MAM SOFTWARE GROUP, INC. Files SEC form 10-Q, Quarterly Report
04:10PM  MAM Software Reports Fiscal Third Quarter Financial Results PR Newswire
07:07AM  Q3 2015 MAM Software Group Inc Earnings Release - After Market Close
May-05-15 04:33PM  MAM Software to Present at the 16th Annual B. Riley & Co. Investors Conference 5th May 2015 at noodls
04:30PM  Parts Central Selects Autopart Business Management Software to Support Company Growth PR Newswire
04:10PM  MAM Software to Present at the 16th Annual B. Riley & Co. Investors Conference PR Newswire
Apr-27-15 09:21AM  MAM Software Group Schedules Conference Call for Thursday, May 7, 2015. 27th April 2015 at noodls
09:00AM  MAM Software Group Schedules Conference Call for Thursday, May 7, 2015 PR Newswire
Mar-31-15 10:40AM  Unisys (UIS) Consortium to Offer IT Services to EFSA - Analyst Blog
Mar-17-15 10:50AM  Unisys (UIS) to Open New Client Service Center in Georgia - Analyst Blog
Mar-16-15 04:00PM  Unisys (UIS) Forms Strategic Partnership with ServiceNow, Shares Down - Analyst Blog
Mar-09-15 12:00PM  Infosys Buys Panaya, Shares Dip on Broader Market Worries - Analyst Blog
Mar-05-15 01:08PM  Andrew Page partners with MAM Software 5 March 2015 at noodls +5.86%
09:31AM  MAM SOFTWARE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibit
Mar-04-15 11:56AM  MAM launches new online booking, website and internet marketing solutions for auto repair shops 3 February 2015 at noodls
11:30AM  MAM launches new online booking, website and internet marketing solutions for auto repair shops PR Newswire
Mar-02-15 05:17PM  Infosys Fortifies TNT's Outlook Program on 5-Year Deal - Analyst Blog
Feb-25-15 09:22AM  MAM Software and Phocas Software announce strategic partnership 25 February 2015 at noodls
09:00AM  MAM Software and Phocas Software announce strategic partnership PR Newswire
MAM Software Group, Inc., through its subsidiaries, provides software, information, and related services to businesses engaged in the automotive aftermarket in the United States, Canada, the United Kingdom, and Ireland. The company offers business management systems that comprise its proprietary software applications, implementation and training, and third-party hardware and peripherals; information products, such as an accessible catalog database related to parts, tires, labor estimates, scheduled maintenance, repair information, technical service bulletins, pricing and product features, and benefits that are used by various participants in the automotive aftermarket; online services and products, which provide online connectivity between manufacturers, warehouse distributors, retailers, and automotive service providers; and customer support, and consulting and training services. Its business management solutions include Autopart, which is designed for and targeted at warehouse distributors that seek to manage multiple locations and inventories on a single system; Autopart that is designed for and targeted at parts store chains that seek to manage various locations and inventories on a single system for a regional area; VAST, a product designed for and targeted at large-to medium- sized automotive service and tire chains; Autowork Online, which is designed for and targeted at automotive installers; and Trader, a product designed for and targeted at generic wholesalers and distributors. In addition, the company provides information products, including Autocat+, an auto parts catalog; online e-commerce services; and Autonet online services. It serves wholesale parts and tire distributors, retailers, franchisees, cooperatives, auto service chains, and single location auto service businesses. The company is headquartered in Barnsley, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 17Buy5.98915442,271,732Jun 20 04:39 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 17Buy5.9841245986,637Jun 20 04:39 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 16Buy5.947564,4912,271,641Jun 20 04:39 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 16Buy5.943442,043986,596Jun 20 04:39 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 15Buy5.902061,2152,270,885Jun 16 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 15Buy5.9094555986,252Jun 16 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 14Buy5.99694132,270,679Jun 16 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 14Buy5.9931186986,158Jun 16 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 10Buy5.982,06312,3372,270,610Jun 13 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 10Buy5.989375,603986,127Jun 13 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 09Buy5.801,1696,7802,268,547Jun 13 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 09Buy5.805313,080985,190Jun 13 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 07Buy5.993,10518,5992,267,378Jun 09 04:30 PM
WYNNEFIELD PARTNERS SMALL CAP 10% OwnerJun 07Buy5.991,4088,434984,659Jun 09 04:30 PM
MNOV MediciNova, Inc. daily Stock Chart
MNOV [NASD]
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own0.20% Shs Outstand34.32M Perf Week-1.79%
Market Cap206.61M Forward P/E- EPS next Y-0.34 Insider Trans46.54% Shs Float29.85M Perf Month2.21%
Income-10.90M PEG- EPS next Q-0.09 Inst Own27.60% Short Float8.13% Perf Quarter-18.32%
Sales- P/S- EPS this Y1.00% Inst Trans27.24% Short Ratio31.35 Perf Half Y-6.96%
Book/sh1.00 P/B6.02 EPS next Y10.50% ROA-26.10% Target Price11.00 Perf Year13.58%
Cash/sh0.70 P/C8.57 EPS next 5Y20.00% ROE-29.60% 52W Range4.55 - 10.16 Perf YTD-0.17%
Dividend- P/FCF- EPS past 5Y22.70% ROI- 52W High-40.75% Beta0.56
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low32.31% ATR0.20
Employees10 Current Ratio15.20 Sales Q/Q- Oper. Margin- RSI (14)45.28 Volatility2.17% 3.60%
OptionableYes Debt/Eq0.00 EPS Q/Q54.00% Profit Margin- Rel Volume0.67 Prev Close6.04
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 AMC Payout- Avg Volume77.39K Price6.02
Recom1.00 SMA200.79% SMA50-4.19% SMA200-10.27% Volume51,990 Change-0.33%
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Feb-18-17 01:04PM  MEDICINOVA INC Financials
Feb-15-17 08:42AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Feb-14-17 06:26PM  MEDICINOVA INC Files SEC form 10-K, Annual Report
Feb-07-17 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston GlobeNewswire
Feb-06-17 06:00PM  MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research GlobeNewswire
Feb-01-17 06:00PM  MediciNova to Attend Mizuho Healthcare Conference in New York GlobeNewswire
Jan-23-17 06:00PM  MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence GlobeNewswire
Dec-22-16 11:30AM  MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion
Dec-20-16 06:00PM  MediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire -6.52%
Dec-19-16 06:00AM  MediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis GlobeNewswire
Dec-15-16 10:32AM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016
Dec-14-16 06:00AM  MediciNova Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-09-16 06:00AM  MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland GlobeNewswire
Nov-14-16 06:00AM  MediciNova to Present at the Piper Jaffray Healthcare Conference in New York GlobeNewswire +6.73%
Nov-10-16 05:02PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:00AM  MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire
Nov-07-16 06:00PM  MediciNova to Attend Global Mizuho Investor Conference in New York GlobeNewswire
Oct-30-16 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland GlobeNewswire
Oct-27-16 11:00AM  MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS
Oct-26-16 10:20AM  MediciNova reports 3Q loss
06:05AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-25-16 05:20PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Oct-11-16 07:00PM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire
02:35PM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016
Sep-25-16 07:00PM  Options on MediciNova Common Stock Listed on CBOE GlobeNewswire
Sep-16-16 05:17PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Jul-29-16 12:00PM  MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16
Jul-27-16 06:12AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Jul-26-16 05:18PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Jul-24-16 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis GlobeNewswire
Jul-13-16 06:30AM  MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
Jun-29-16 07:00PM  MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana GlobeNewswire
Jun-26-16 07:00PM  MediciNova Added to Russell 3000® Index and Russell Global Index GlobeNewswire
Jun-13-16 06:08AM  MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +5.18%
Jun-06-16 02:27PM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
May-25-16 07:00PM  MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana GlobeNewswire
Apr-29-16 04:25PM  MNOV: Positive Trends Seen in Preliminary Data Presented on MN-166 in ALS
Apr-28-16 06:21AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Apr-27-16 04:55PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Apr-20-16 06:00AM  MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada GlobeNewswire -6.56%
Apr-04-16 08:02AM  MediciNova, Inc. (NASDAQ: MNOV) - Analyst Coverage Initiated; Report by Broad Street Accesswire +13.92%
Mar-31-16 07:55AM  MediciNova Gains 6% Following Positive Mention In Medical Journal
06:32AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offic
Mar-30-16 07:00PM  MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire +11.11%
Mar-27-16 07:20PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China at noodls
07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China GlobeNewswire
Mar-23-16 07:27PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia at noodls
07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia GlobeNewswire
Mar-22-16 06:29AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis at noodls
06:09AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis GlobeNewswire
Mar-14-16 01:57PM  LifeSci Capital Initiates Coverage of MediciNova Accesswire
09:00AM  Biotech Trade Report Accesswire
Mar-09-16 11:00AM  MNOV: Multiple Catalysts Ahead in 2016
Mar-07-16 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire
Mar-06-16 06:00PM  MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas GlobeNewswire
Mar-01-16 08:46AM  MediciNova, Inc. (NASDAQ: MNOV) Ongoing Clinical Trial of MN-166 Accesswire
Feb-26-16 09:15AM  3 Stocks That Should be in Your Portfolio Today Accesswire -10.59%
06:41AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Feb-25-16 05:19PM  MEDICINOVA INC Files SEC form 10-K, Annual Report +10.69%
03:04PM  3 Biotech Stocks to Consider Buying Right Now Accesswire
10:15AM  4 Stocks That Are Starting To Attract Major Attention Today Accesswire
Feb-22-16 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada GlobeNewswire +5.98%
Feb-11-16 06:00PM  MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Feb-07-16 06:00PM  MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Jan-27-16 06:18PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis at noodls
06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis GlobeNewswire
Jan-18-16 06:00PM  FDA Grants Rare Pediatric Disease Designation to MediciNovas MN-166 (ibudilast) for the Treatment of Krabbe Disease GlobeNewswire
Jan-13-16 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe GlobeNewswire
Dec-16-15 02:30PM  MNOV: Positive Interim Safety and Clinical Data Presented at 26th International Symposium on ALS/MND
06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis GlobeNewswire
Dec-14-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China GlobeNewswire
Dec-13-15 06:00PM  MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Dec-09-15 05:30PM  MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting GlobeNewswire
Dec-06-15 06:00PM  MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, California GlobeNewswire
Dec-02-15 07:45AM  Evaluating the Technicals - Research on Hudson Technologies, Retractable Technologies, Spark Networks and MediciNova Accesswire
Nov-27-15 08:06AM  Is MediciNova, Inc. (MNOV) A Good Stock To Buy? at Insider Monkey
Nov-23-15 09:56AM  Is Timmins Gold Corp (TGD) A Good Stock To Buy? at Insider Monkey
Nov-19-15 06:00AM  MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia GlobeNewswire
Nov-10-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan GlobeNewswire
Nov-09-15 06:00PM  FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital) GlobeNewswire
Nov-04-15 06:00AM  MediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at the 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting in Clearwater Beach, Florida GlobeNewswire
Nov-02-15 03:00PM  MNOV: Presentation on ALS Phase 2 Study in December
Oct-30-15 06:14AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-29-15 05:19PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Oct-13-15 07:00PM  MediciNova to Present Preclinical Data on MN-166 (ibudilast) at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Oct-09-15 06:00AM  MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF GlobeNewswire
Sep-25-15 05:11PM  15 Stocks Moving In Friday's After-Hours Trading
05:02PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-24-15 06:00AM  MediciNova to Present at the Ladenburg Thalmann 2015 Healthcare Conference GlobeNewswire
Sep-10-15 06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-08-15 11:35AM  MNOV: Phase 2 ALS Trial Expanded
Sep-02-15 07:00PM  MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast) GlobeNewswire
Sep-01-15 06:06AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Aug-25-15 06:04AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-24-15 07:00PM  MediciNova Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Aug-19-15 06:07AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-18-15 07:43PM  MediciNova Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire
05:01PM  Tuesday's After-Hours Movers Led By Analog Devices, Canadian Solar And Weibo
04:00PM  MediciNova Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Aug-03-15 01:45PM  MNOV: Ready to Initiate Phase 2 Trials of MN-001 in IPF and NASH
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kobayashi YutakaDirectorSep 15Buy6.4411,80075,99281,800Sep 15 02:10 PM
Kobayashi YutakaDirectorSep 09Buy6.6710,00066,70070,000Sep 09 06:29 PM
OBrien GeoffreyVice PresidentJul 05Option Exercise4.803,30015,8408,300Jul 07 06:30 PM
OBrien GeoffreyVice PresidentJul 05Sale8.003,30026,4005,000Jul 07 06:30 PM